Ohara et al. [91] believed that AMSC-EVs can inhibit p65 and IκB-α phosphorylation and the activities of transcription in NF-κB. However, AMSC-EVs could not inhibit the transcription activities in TNF receptor-associated factor 6 from HEK293 cells, further indicating that AMSC-EVs may improve the progression of NASH through the LPS/TLR4 pathway. Here, TLR4 is linked to metabolic dysfunction-associated steatohepatitis.